Skip to main content
main-content

05-10-2017 | Rheumatology | News | Article

News in brief

‘No vascular protective effect’ of HCQ in patients with SLE

medwireNews: Long-term hydroxychloroquine (HCQ) therapy is not associated with a reduced risk for vascular events among patients with systemic lupus erythematosus (SLE), Taiwanese researchers report.

In a database study, Tien-Hsing Chen (Chang Gung University College of Medicine, Keelung) and co-authors found that 7.1% of 1946 HCQ-treated patients experienced an acute coronary syndrome, ischemic stroke, pulmonary embolism, or deep vein thrombosis over a mean follow-up of 7.4 years, compared with 7.7% of 1946 patients who were not treated with HCQ.

These findings translate into a comparable risk for vascular events between the two groups, with a hazard ratio of 0.91, and the results were consistent in subgroup analyses of different HCQ doses, report the researchers in Rheumatology.

Therefore, “[l]ong-term HCQ appears to have no vascular protective effect in patients with SLE,” write Chen and colleauges.

And they conclude that “[f]urther studies in other ethnic groups will be necessary to further validate the results of the present study.”

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group